Original Article
Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery
N Engl J Med 2001; 345:1305-1310November 1, 2001
- Abstract
Background
Despite thromboprophylaxis, major knee surgery carries a high risk of venous thromboembolism. Fondaparinux, the first of a new class of synthetic antithrombotic agents, may reduce this risk.
Methods
In a double-blind study, we randomly assigned 1049 consecutive patients undergoing elective major knee surgery to receive subcutaneous doses of either 2.5 mg of fondaparinux once daily or 30 mg of enoxaparin twice daily, with both treatments initiated postoperatively. The primary efficacy outcome was venous thromboembolism up to postoperative day 11, defined as deep-vein thrombosis detected by mandatory bilateral venography, documented symptomatic deep-vein thrombosis, or documented symptomatic pulmonary embolism. The primary safety outcome was major bleeding.
Results
The primary efficacy outcome was assessed in 724 patients. The fondaparinux group had a significantly lower incidence of venous thromboembolism by day 11 (12.5 percent [45 of 361 patients]) than the enoxaparin group (27.8 percent [101 of 363 patients]; reduction in risk, 55.2 percent; 95 percent confidence interval, 36.2 to 70.2; P<0.001). Major bleeding (including overt bleeding with a bleeding index of 2 or more) occurred more frequently in the fondaparinux group (P=0.006), but there were no significant differences between the two groups in the incidence of bleeding leading to death or reoperation or occurring in a critical organ.
Conclusions
In patients undergoing elective major knee surgery, postoperative treatment with 2.5 mg of fondaparinux once daily was significantly more effective in preventing deep-vein thrombosis than 30 mg of enoxaparin twice daily.
Media in This Article
Table 1
Patients Included in the Analyses and Reasons for Exclusion.Table 2
Base-Line Characteristics of the Patients.Article Activity
- Article
Venous thromboembolism is a frequent, life-threatening postoperative complication of total-knee-replacement surgery.1,2 Without thromboprophylaxis, the prevalence rate is 40 to 84 percent for venographically verified postoperative deep-vein thrombosis and 2 to 7 percent for pulmonary embolism.1 Thromboprophylaxis that is effective in hip-replacement surgery, such as low-dose heparin, low-molecular-weight heparin, or warfarin, is less successful in knee-replacement surgery and reduces the prevalence of deep-vein thrombosis only to 31 to 47 percent.1 For this reason, more effective antithrombotic prophylaxis is needed in knee-replacement surgery.
Fondaparinux is one of a new class of antithrombotic agents, the selective inhibitors of activated factor X (factor Xa).3-6 Fondaparinux is an entirely synthetic pentasaccharide that is structurally related to the antithrombin-binding site of heparin. In contrast to heparin, which interacts with many plasma components, the pentasaccharide selectively binds to antithrombin, causing it to rapidly inhibit factor Xa, a key enzyme in the coagulation pathway. Recent dose-ranging studies suggested that a once-daily subcutaneous injection of 2.5 mg of fondaparinux can prevent venous thromboembolism after hip-replacement7 or knee-replacement surgery (unpublished data).
This multicenter, randomized, double-blind trial was part of a program that also evaluated fondaparinux as prophylaxis against venous thromboembolism in patients undergoing surgery for hip fracture8 and elective hip replacement.9,10 The aim of the study was to compare the efficacy and safety of a once-daily subcutaneous injection of 2.5 mg of pentasaccharide with twice-daily subcutaneous injections of 30 mg of enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
Methods
Patients
Patients were considered for inclusion if they were at least 18 years of age and were undergoing elective major knee surgery — that is, surgery requiring resection of the distal end of the femur or proximal end of the tibia or revision of at least one component of a previously implanted total-knee prosthesis.
Patients were excluded if surgery in the contralateral knee was performed at the same time or within two weeks after enrollment. Women were excluded if they were pregnant or not using effective contraception. Other main reasons for exclusion were active bleeding; a documented congenital or acquired bleeding disorder; current ulcerative or angiodysplastic gastrointestinal disease; hemorrhagic stroke or brain, spinal, or ophthalmologic surgery within the previous three months; insertion of an indwelling intrathecal or epidural catheter during the treatment period; unusual difficulty in administering epidural or spinal anesthesia (e.g., more than two attempts); hypersensitivity to heparin, low-molecular-weight heparins, porcine products, or iodinated contrast medium; a contraindication to anticoagulant therapy; a current addictive disorder; a serum creatinine concentration above 2 mg per deciliter (177 μmol per liter) in a well-hydrated patient; and a platelet count below 100,000 per cubic millimeter. Finally, patients who required anticoagulant therapy were also excluded. The use within one week before randomization of dextran or any type of anticoagulant, fibrinolytic, or antiplatelet agent was discouraged.
Study Design
Immediately after surgery, patients were randomly assigned (in a ratio of 1:1 in blocks of four, stratified according to center), through a central computer-derived randomization scheme to receive subcutaneous doses of either 2.5 mg of fondaparinux (Arixtra, NV Organon, Oss, the Netherlands, and Sanofi–Synthelabo, Paris) once daily and a placebo once daily or 30 mg of enoxaparin (Clexane/Lovenox, Aventis Pharmaceuticals, Bridgewater, N.J.) twice daily. In the enoxaparin group, the first dose was given between 12 and 24 hours after surgery, according to the recommendation of the manufacturer. Since fondaparinux is a new compound, which differs from enoxaparin in its mechanism of action and pharmacokinetic properties, the starting time after surgery and the dose were determined during the early development of the drug7; the first postoperative injection was administered 6±2 hours after surgery and the second injection 12 hours or more after the first.
The day of surgery was defined as day 1. Treatment was scheduled to continue until day 5 to day 9, and the primary efficacy outcome was assessed between day 5 and day 11. Patients were then followed up in person, by mail, or by telephone between day 35 and day 49. During follow-up, patients were instructed to report any symptoms or signs of venous thromboembolism or bleeding and any other clinical event occurring since the completion of treatment. Investigators could extend prophylaxis during follow-up with any currently available therapy, but only after venography had been performed. If venous thromboembolism occurred during the study, treatment was left to the discretion of the investigator.
The study was conducted according to the ethical principles stated in the Declaration of Helsinki and local regulations. The protocol was approved by independent local institutional review boards, and written informed consent was obtained from all patients before randomization.
Medications
Study medications were packaged in boxes of identical appearance, each containing 19 prefilled, single-dose syringes: 10 syringes of fondaparinux and 9 syringes of placebo for each patient assigned to fondaparinux, or 18 syringes of enoxaparin and 1 syringe of placebo for each patient assigned to enoxaparin. Each syringe contained 2.5 mg of fondaparinux sodium in 0.25 ml of water for injectable preparations (a concentration of 10 mg per milliliter), 30 mg of enoxaparin sodium in 0.3 ml of water for injectable preparations (a concentration of 100 mg per milliliter), or placebo (0.25 or 0.3 ml of isotonic saline). Each syringe was loaded inside an opaque autoinjector (Autoject, Owen Mumford, Woodstock, United Kingdom) to maintain blinding.
Throughout the treatment period, the use of intermittent pneumatic compression, dextran, and any other anticoagulant, thrombolytic, or antiplatelet agent was prohibited. Centers were advised to avoid giving patients aspirin or nonsteroidal antiinflammatory drugs whenever possible. The use of graduated-compression stockings and physiotherapy was recommended.
Outcome Measures
The primary efficacy outcome was assessed by the rate of venous thromboembolism (defined as deep-vein thrombosis, pulmonary embolism, or both) up to day 11. Secondary efficacy outcomes were total, proximal, or distal deep-vein thrombosis or symptomatic venous thromboembolism up to day 11 and symptomatic venous thromboembolism up to day 49. Patients were examined for deep-vein thrombosis by systematic bilateral ascending venography of the legs11 between day 5 and day 11, but no more than two days after the last injection of study drug, or earlier if thrombosis was clinically suspected. Symptomatic pulmonary embolism was confirmed by a lung scan indicating a high probability of pulmonary embolism, pulmonary angiography,12 or helical computed tomography or at autopsy.
The primary safety outcome was the incidence of major bleeding, which included fatal bleeding; bleeding that was retroperitoneal, intracranial, or intraspinal or that involved any other critical organ; bleeding leading to reoperation; and overt bleeding with a bleeding index of 2 or more. The bleeding index was calculated as the number of units of packed red cells or whole blood transfused plus the hemoglobin values before the bleeding episode minus the hemoglobin values after the episode (in grams per deciliter). Secondary safety outcomes were death, other bleeding, a need for transfusion, thrombocytopenia, and any other adverse event.
Efficacy and safety outcomes were adjudicated by a central independent committee whose members were unaware of the treatment assignments and included reviews of all venograms and reports of bleeding and death.
Statistical Analysis
Assuming an incidence of venous thromboembolism by day 11 of 34 percent in the enoxaparin group and a risk reduction of about 30 percent (i.e., an incidence of 24 percent in the fondaparinux group), 319 patients were needed in each group (for a total of 638 patients) to provide the study with a power of 85 percent. The target number of recruited patients was 912, a number that allowed for failure to obtain primary efficacy data in up to 30 percent of patients.
The analysis of the primary efficacy outcome included data on all patients who had received at least one dose of study medication, had undergone the appropriate surgery, and had had an adequate assessment for venous thromboembolism by day 11. The analysis of safety included data on patients who had received at least one dose of study medication.
A two-tailed P value of less than 0.05 was considered to indicate statistical significance. The analysis of the primary efficacy outcome was performed with the use of a two-sided Fisher's exact test. Exact 95 percent confidence intervals for the absolute difference between fondaparinux and enoxaparin and the risk ratio were calculated. The treatment effect was also analyzed according to predefined categorical covariates with the use of a logistic-regression model.
The study was supervised by a steering committee of 11 people, which included 7 representatives of the sponsors (NV Organon and Sanofi–Synthelabo). The committee designed the study, interpreted the data, and wrote the article. The final statistical analysis was performed by the sponsor. The central adjudication committee and the data monitoring committee operated independently of the sponsor. One planned interim analysis was conducted by an independent statistical center when half the projected patient population had been enrolled, for reestimation of the sample size, since the rate of venous thromboembolism in patients undergoing knee surgery was uncertain. Simulations demonstrated that the predefined procedure did not inflate the type I error. No change in the sample size was found to be necessary, and the study continued as planned.
Results
Study Populations
Between December 1998 and January 2000, 1049 patients were enrolled in 64 centers in North America. Fifteen patients did not receive any study drug, leaving 1034 available for the safety analysis (Table 1Table 1
Patients Included in the Analyses and Reasons for Exclusion.); primary efficacy had not been assessed by day 11 in 310 patients. Thus, 724 patients (69.0 percent) were included in the primary efficacy analysis, a percentage in line with other large multicenter trials that used venography after orthopedic surgery.13-16 The characteristics of patients excluded from the primary efficacy analysis did not differ from those of patients included in the analysis (data not shown).Base-line characteristics did not differ significantly between the two groups of patients included in the analysis of safety (Table 2Table 2
Base-Line Characteristics of the Patients.) or primary efficacy (data not shown). Among patients analyzed for primary efficacy, the median time between surgery and the qualifying examination for venous thromboembolism was seven days in both groups; most patients underwent this examination between day 5 and day 11, as planned. The two groups did not differ with regard to the last day of active treatment or the use of concomitant treatments up to day 11 (Table 3Table 3
Treatments Received during the Study Period by Patients Assessed for the Primary Efficacy Outcome.).Overall, 514 patients treated with fondaparinux and 511 patients treated with enoxaparin returned for the follow-up visit on day 49. The duration of follow-up was similar in the two groups. During follow-up of patients who were not treated for an acute thromboembolic event, 19.1 percent of patients assigned to fondaparinux (86 of 450) and 20.2 percent of patients assigned to enoxaparin (82 of 406) received prolonged thromboprophylaxis, primarily with a preparation of heparin or a vitamin K antagonist.
Incidence of Venous Thromboembolism
The incidence of venous thromboembolism by day 11 was 27.8 percent (101 of 363 patients) in the enoxaparin group and 12.5 percent (45 of 361 patients) in the fondaparinux group (reduction in risk, 55.2 percent; 95 percent confidence interval, 36.2 to 70.2 percent; P<0.001) (Table 4Table 4
Incidence of Venous Thromboembolic Events by Day 11.). A similar result was found in sensitivity analyses when patients who had had no primary efficacy assessment by day 11 were included in the primary efficacy analysis (data not shown). As compared with enoxaparin, fondaparinux reduced the incidence of proximal deep-vein thrombosis by 54.5 percent (P=0.06) and distal deep-vein thrombosis by 55.9 percent (P<0.001). The incidence of symptomatic venous thromboembolism was low and did not differ significantly between the two groups (Table 4). Overall, the superiority of fondaparinux over enoxaparin with respect to primary efficacy was consistent according to age, sex, body-mass index (the weight in kilograms divided by the square of the height in meters [<30 vs. ≥30]), type of anesthesia (general, regional, or both), type of surgery (primary or revision), use or nonuse of cement, and whether or not patients had had previous venous thromboembolism (data not shown). The number of patients treated by participating physicians for a venous thromboembolic event by day 11 was significantly lower in the fondaparinux group (15.1 percent [67 of 443]) than in the enoxaparin group (25.1 percent [111 of 442], P<0.001).By day 49, the incidence of symptomatic venous thromboembolism did not differ significantly between the fondaparinux group (1.0 percent [5 of 517 patients]) and the enoxaparin group (1.9 percent [10 of 517 patients]). Fatal pulmonary embolism occurred in one patient in each group; nonfatal pulmonary embolism occurred in two patients in the fondaparinux group and four in the enoxaparin group.
Safety Outcomes
There were no instances of fatal bleeding or bleeding in a critical organ in either treatment group; bleeding requiring reoperation occurred in two patients in the fondaparinux group and one in the enoxaparin group. In all three patients, drainage of a knee effusion was performed. In the fondaparinux group, nine episodes of overt bleeding were associated with a bleeding index of 2 or more; seven occurred at the surgical site, and only three led to discontinuation of study treatment. The total for the primary safety outcome was therefore 11 major bleeding episodes in the fondaparinux group and 1 in the enoxaparin group (P=0.006) (Table 5Table 5
Safety Outcomes.). The incidence of minor bleeding, a need for transfusion, and other adverse events during treatment or follow-up did not differ significantly between the two groups. Platelet counts lower than 100,000 per cubic millimeter were measured in 14 patients (2.7 percent) in the fondaparinux group as compared with 19 (3.7 percent) in the enoxaparin group (P=0.27). No episode of a decreased platelet count was reported as a serious adverse event in either group. By day 49, two patients in the fondaparinux group (0.4 percent) and three in the enoxaparin group (0.6 percent) had died from causes unrelated to the treatment.Discussion
This study demonstrates that fondaparinux is significantly more effective than enoxaparin in preventing venous thromboembolism after elective major knee surgery. Deep-vein thrombosis has been more difficult to prevent with anticoagulation therapy after knee surgery than after total hip replacement, even with low-molecular-weight heparin, the most effective thromboprophylactic therapy to date.1 The 27.8 percent incidence of venous thromboembolic events in the enoxaparin group by day 11 is consistent with the incidence of 19.0 to 25.0 percent in other trials of enoxaparin after knee surgery.16-19 In our study, the reduction to 12.5 percent in the fondaparinux group is consistent with the results of three other large studies in patients undergoing surgery for hip fracture8 or elective hip replacement.9,10 The superior efficacy of fondaparinux may be related to its ability to initiate selective inhibition of factor Xa, its predictable linear pharmacokinetics, the choice of dose, and the starting time after surgery.
The low incidence of symptomatic events in our study should be interpreted with caution, as it is likely to be lower than would be observed in typical clinical situations. As in other trials of thromboprophylaxis, most of our asymptomatic patients with positive venograms had been receiving an anticoagulant at a therapeutic dose. Moreover, about 20 percent of our patients were receiving prophylaxis after the study treatment period ended. Both of these factors may have prevented symptomatic venous thrombosis.
Major bleeding was significantly more frequent in the fondaparinux group (11 patients, including 9 with a bleeding index of 2 or more) than in the enoxaparin group (1 patient). Administration of fondaparinux was continued in six of the nine patients with a bleeding index of 2 or more. Nevertheless, the two groups did not differ significantly with respect to fatal bleeding, bleeding in critical organs, or bleeding leading to reoperation.
Presented in abstract form at the 42nd Annual Meeting of the American Society of Hematology, San Francisco, December 1–5, 2000 (Blood 2000;9:491A, A2111).
Supported by NV Organon and Sanofi–Synthelabo. All authors have served as consultants to NV Organon and Sanofi–Synthelabo.
Source Information
From the Department of Medicine, Veterans Affairs Boston Healthcare System and Beth Israel Deaconess Medical Center, Boston (K.A.B.); the Department of Orthopedics, Sahlgrenska University Hospital–Östra, Göteborg, Sweden (B.I.E.); the Department of Orthopedics, Hillerød University, Hillerød, Denmark (M.R.L.); and the Department of Medicine, Hamilton Health Sciences Corporation–General Division, Hamilton, Ont., Canada (A.G.G.T).
Address reprint requests to Dr. Bauer at the Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston, MA 02215, or at kbauer@caregroup.harvard.edu.
Participants in the study are listed in the Appendix.
Appendix
The members of the Pentasaccharide in Major Knee Surgery Study Group were as follows: Steering Committee — A.G.G. Turpie (chair), K.A. Bauer, J. Bouthier, R.G. Cariou, J.F.M. Egberts, B.I. Eriksson, J.A. Hoek, M.R. Lassen, A.W.A. Lensing, H. Magnani, L. Snow-Adami; Data Monitoring Committee — D. Bergqvist, G.D. Paiement, A. Planes; Central Independent Adjudication Committee — M. Gent (chair), J.S. Ginsberg, J. Hirsh, C. Kearon, M.N. Levine, J.G. Thomson, A.G.G. Turpie, J. Weitz; Independent Statistical Center — A. Leizorovicz, Lyons, France; Sponsor, NV Organon, the Netherlands — Study Management: L. Snow-Adami, E. Warga; Statistical Analysis: R. Vijayaraghavan, W.F. Sommer; Clinical Documentation: E. Osifchin; Investigators, United States (861 patients) — N. Abramson, Jacksonville, Fla.; J. Albrigo, Alexandria, Va.; J. Barnett, Orlando, Fla.; K. Beer, Toledo, Ohio; B. Bierbaum, Boston; W. Bose, West Mobile, Ala.; D. Bramlet, St. Petersburg, Fla.; F. Burke, Lexington, Ky.; D. Butler, Sacramento, Calif.; V. Cabanas and M. Swank, Cincinnati; F. Cannon, Ocala, Fla.; J. Caraveo, Temple, Tex.; C. Chalian, Pomona, Calif.; C. Christensen, J. Muntz, and S. Siff, Houston; P. Comp, Oklahoma City; D. Covall, Decatur, Ga.; R. Ennis, Hollywood, Fla.; G.S. Gill, Lubbock, Tex.; D. Green, Chicago; D. Gremillion, Nashville; N. Halbridge, Fountain Valley, Calif.; W. Hefley, R. Lavender, and R.B. Sorrells, Little Rock, Ark.; M. Hollman, Orlando, Fla.; W. Hopkinson, Maywood, Ill.; C. Hummer, Upland, Pa.; F. Ivey, Galveston, Tex.; A. Jahnke, Fort Gordon, Ga.; G. Johnson, Minneapolis; G. Kantor, Palm Beach Gardens, Fla.; H. Kim, San Francisco; W. Kim, Fountain Valley, Calif.; M. Koren, South Jacksonville, Fla.; W. Lanzer, Seattle; D. Lawlor, Olathe, Kans.; L. Levy, La Mesa, Calif.; A. Lombardi, Columbus, Ohio; P. Lunseth, Tampa, Fla.; D. MacDonald, East Lansing, Mich.; M. Mancao, Pensacola, Fla.; G. Mayfield, Honolulu; J. Ohar, St. Louis; P. Peters, Dallas; K. Plancher, Stamford, Conn.; P. Richin, Decatur, Ga.; D. Riff, Anaheim, Calif.; M. Ritter, Mooresville, Ind.; L. Rocamora, Winston-Salem, N.C.; W. Shelton, Jackson, Miss.; B. Spetzler, Salem, Va.; E. Strauss, Great Neck, N.Y.; J. Tozzi, Neptune, N.J.; C. Walker, Whittier, Calif.; L. Walker, San Bernardino, Calif.; M. Ward, Covina, Calif.; C. Williamson, South Daytona, Fla.; and I. Ziv, Buffalo, N.Y.; Investigators, Canada (188 patients) — D. Anderson and M. Gross, Halifax, N.S.; R. Bhargava, Oshawa, Ont.; J. Brandwein and J. Gollish, Toronto; L. Desjardins, Ste. Foy, Que.; M. Mant, Edmonton, Alta.; W. Pisesky, Kelowna, B.C.; B. Pressnail, Barrie, Ont.; M. Rodger, Ottawa, Ont.; S. Solymoss, Montreal; T. Sparling, Burnaby, B.C.; and J. Wilson, North York, Ont.
- References
References
1
Geerts WH ,Heit JA ,Clagett GP , et al. Prevention of venous thromboembolism. Chest 2001;119:Suppl:132S-175S
CrossRef | Web of Science | Medline2
Nicolaides AN . Prevention of venous thromboembolism: international consensus statement: guidelines compiled in accordance with the scientific evidence. Int Angiol 2001;20:1-37
CrossRef | Web of Science | Medline3
Lormeau JC ,Herault JP . The effect of the synthetic pentasaccharide SR 90107/ORG31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost 1995;74:1474-1477
Web of Science | Medline4
Walenga JM ,Bara L ,Petitou M ,Samama MM ,Fareed J ,Choay J . The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Thromb Res 1988;51:23-33
CrossRef | Web of Science | Medline5
Petitou M ,Lormeau J-C ,Choay J . Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs. Nature 1991;350:Suppl:30-33
Web of Science | Medline6
van Boeckel CAA ,Petitou M . The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew Chem Int Ed Engl 1993;32:1671-1690
CrossRef | Web of Science7
Turpie AGG ,Gallus AS ,Hoek JA . A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001;344:619-625
Full Text | Web of Science | Medline8
Eriksson BI ,Bauer KA ,Lassen MR ,Turpie AGG . Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-1304
Full Text | Web of Science | Medline9
Lassen MR . The EPHESUS Study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery. Blood 2000;96:490a-490a abstract.
Web of Science10
Turpie G . The PENTATHLON 2000 Study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery. Blood 2000;96:491a-491a abstract.
Web of Science11
Rabinov K ,Paulin S . Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972;104:134-144
CrossRef | Web of Science | Medline12
The PIOPED Investigators
CrossRef | Web of Science13
Eriksson BI ,Ekman S ,Kalebo P ,Zachrisson B ,Bach D ,Close P . Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996;347:635-639
CrossRef | Web of Science | Medline14
Hull RD ,Pineo GF ,Francis C , et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. Arch Intern Med 2000;160:2199-2207
CrossRef | Web of Science | Medline15
Heit JA ,Berkowitz SD ,Bona R , et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Thromb Haemost 1997;77:32-38
Web of Science | Medline16
Leclerc JR ,Geerts WH ,Desjardins L , et al. Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996;124:619-626
Web of Science | Medline17
Leclerc JR ,Geerts WH ,Desjardins L , et al. Prevention of deep vein thrombosis after major knee surgery -- a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992;67:417-423
Web of Science | Medline18
Spiro TE ,Fitzgerald RH ,Trowbridge AA , et al. Enoxaparin, a low molecular weight heparin and warfarin for the prevention of venous thromboembolic disease after elective knee replacement surgery. Blood 1994;84:Suppl:246a-246a abstract.
Web of Science19
Spiro TE ,Colwell CW ,Bona RD , et al. A clinical trial comparing the efficacy and safety of enoxaparin, a low molecular weight heparin and unfractionated heparin for the prevention of deep venous thrombosis after elective knee replacement surgery. Blood1993;82:410a-410a abstract.
Web of Science
- Citing Articles (211)
Citing Articles
1
Ernest Kwek, Richard E. Buckley. 2011. Thromboprophylaxis in Orthopedic Practice. , 56-71.
CrossRef2
J. Elmer, K. A. Wittels. (2011) Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature. Transfusion Medicineno-no
CrossRef3
Michael Nagler, Michael Haslauer, Walter A. Wuillemin. (2011) Fondaparinux – data on efficacy and safety in special situations. Thrombosis Research
CrossRef4
Richard J. Friedman. (2011) Novel Oral Anticoagulants for VTE Prevention in Orthopedic Surgery: Overview of Phase 3 Trials. Orthopedics 34:10, 795-804
CrossRef5
Nancy Torres Finnerty, Franklin Michota. 2011. Prevention of Venous Thromboembolism in Surgical Patients. , 107-136.
CrossRef6
Mark J. Fesler, Michael H. Creer, John M. Richart, Randall Edgell, Necat Havlioglu, Gershom Norfleet, Salvador Cruz-Flores. (2011) Heparin-Induced Thrombocytopenia and Cerebral Venous Sinus Thrombosis: Case Report and Literature Review. Neurocritical Care 15:1, 161-165
CrossRef7
Gustavo Cumbo-Nacheli, Lobelia Samavati, Jorge A. Guzman. (2011) Bioavailability of fondaparinux to critically ill patients. Journal of Critical Care 26:4, 342-346
CrossRef8
O. Cousin, C. Le Hello, M.-T. Barrellier. (2011) Incidence et distribution des thromboses veineuses des membres inférieurs diagnostiquées par écho-doppler au décours de prothèses de hanche, de genou et de fractures de hanche. Résultats portant sur 5981 explorations et 2123 thromboses en dix ans. Journal des Maladies Vasculaires 36:4, 243-253
CrossRef9
P. Luporsi, R. Chopard, S. Janin, E. Racadot, Y. Bernard, F. Ecarnot, MF. Séronde, F. Briand, A. Guignier, V. Descotes-Genon, N. Meneveau, F. Schiele. (2011) Use of recombinant factor VIIa (NovoSeven ® ) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. Acute Cardiac Care 13:2, 93-98
CrossRef10
Song Turun, Liao Banghua, Yin Yuan, Li Zhenhui, Nie Ying, Chen Jin. (2011) A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. Thrombosis Research 127:6, 525-534
CrossRef11
Sanjay K Murthy, Geoffrey C Nguyen. (2011) Venous Thromboembolism in Inflammatory Bowel Disease: An Epidemiological Review. The American Journal of Gastroenterology 106:4, 713-718
CrossRef12
Seung-Ho Kang, Yuman Ryu. (2011) The Adjustment of the Type I Error Rate in Noninferiority Trials with λ-Margin Approach: Each of Two Different New Drugs is Approved with Two Independent Trials with the Same Active Control. Journal of Biopharmaceutical Statistics 21:3, 498-510
CrossRef13
Richard J. Friedman, Sylvia Haas. (2011) Strengths and Limitations of Standards of Care to Guide the Orthopedic Surgeon in VTE Prevention. Orthopedics 34:2, 121-128
CrossRef14
R. C. Barker, P. Marval. (2011) Venous thromboembolism: risks and prevention. Continuing Education in Anaesthesia, Critical Care & Pain 11:1, 18-23
CrossRef15
Jeffrey I. Weitz. (2011) Factor Xa and thrombin as targets for new oral anticoagulants. Thrombosis Research 127, S5-S12
CrossRef16
Elisabeth Perzborn, Susanne Roehrig, Alexander Straub, Dagmar Kubitza, Frank Misselwitz. (2011) The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nature Reviews Drug Discovery 10:1, 61-75
CrossRef17
Satoshi Sasaki, Naohisa Miyakoshi, Hiroshi Matsuura, Hidetomo Saito, Toru Nakanishi, Yumiko Kudo, Tomiko Fujiya, Yoichi Shimada. (2011) Prospective study on the efficacies of fondaparinux and enoxaparin in preventing venous thromboembolism after hip fracture surgery. Journal of Orthopaedic Science 16:1, 64-70
CrossRef18
Jawed Fareed, Cafer Adiguzel, Indermohan Thethi. (2011) Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. Thrombosis Journal 9:1, 5
CrossRef19
Yusuke Asakura, Hiroki Tsuchiya, Hisatake Mori, Takashi Yano, Yasuhide Kanayama, Hideki Takagi. (2011) Reduction of the incidence of development of venous thromboembolism by ultrasound-guided femoral nerve block in total knee arthroplasty. Korean Journal of Anesthesiology 61:5, 382
CrossRef20
José Ignacio Abad Rico, Juan Vicente Llau Pitarch, José Antonio Páramo Fernández. (2010) Topical Issues in Venous Thromboembolism. Drugs 70, 11-18
CrossRef21
Timothy A. Morris. (2010) New Synthetic Antithrombotic Agents for Venous Thromboembolism: Pentasaccharides, Direct Thrombin Inhibitors, Direct Xa Inhibitors. Clinics in Chest Medicine 31:4, 707-718
CrossRef22
Hans-Juergen Rupprecht, Ralf Blank. (2010) Clinical Pharmacology of Direct and Indirect Factor Xa Inhibitors. Drugs1
CrossRef23
Toshio Yamaguchi, Masahiro Hasegawa, Rui Niimi, Akihiro Sudo. (2010) Incidence and time course of asymptomatic deep vein thrombosis with fondaparinux in patients undergoing total joint arthroplasty. Thrombosis Research 126:4, e323-e326
CrossRef24
O. E. DAHL, D. J. QUINLAN, D. BERGQVIST, J. W. EIKELBOOM. (2010) A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. Journal of Thrombosis and Haemostasis 8:9, 1966-1975
CrossRef25
Sophie Gerkens, Ralph Crott, Marie-Christine Closon, Yves Horsmans, Claire Beguin. (2010) Comparing the quality of care across Belgian hospitals from medical basic datasets: the case of thromboembolism prophylaxis after major orthopaedic surgery. Journal of Evaluation in Clinical Practice 16:4, 685-692
CrossRef26
Leilei Zeng, Richard J. Cook, Theodore E. Warkentin. (2010) Regression Analysis with a Misclassified Covariate from a Current Status Observation Scheme. Biometrics 66:2, 415-425
CrossRef27
Lars C. Borris. (2010) Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty. Archives of Orthopaedic and Trauma Surgery 130:5, 583-589
CrossRef28
Piercarlo Salari. (2010) Profilassi tromboembolica in chirurgia ortopedica: dalle evidenze delle linee guida alla pratica clinica. LO SCALPELLO-OTODI Educational 24:1, 67-82
CrossRef29
T. E. WARKENTIN, R. J. COOK, V. J. MARDER, A. GREINACHER. (2010) Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. Journal of Thrombosis and Haemostasis 8:3, 504-512
CrossRef30
Stefano Capri, Walter Ageno, Davide Imberti, Gualtiero Palareti, Franco Piovella, Gianluigi Scannapieco, Marco Moia. (2010) Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. Internal and Emergency Medicine 5:1, 33-40
CrossRef31
Takashi Manabe, Toshihiro Ohdera, Masaaki Katsuki. (2010) Bleeding Complications in Anticoagulant Treatment Using Fondaparinux after Total Knee Arthroplasty. Orthopedics & Traumatology 59:2, 216-219
CrossRef32
Richard J. Friedman. (2010) New Oral Anticoagulants for Thromboprophylaxis after Elective Total Hip and Knee Arthroplasty. Thrombosis 2010, 1-9
CrossRef33
Geoffrey H. Westrich, Lindsey J. Bornstein. (2009) Prophylactic Modalities: Pharmacologic and Mechanical Compression. Seminars in Arthroplasty 20:4, 235-240
CrossRef34
Clifford W. Colwell. (2009) The ACCP Guidelines for Thromboprophylaxis in Total Hip and Knee Arthroplasty. Orthopedics 32:12/Supplement, 67-73
CrossRef35
Jong-Ping Lu, M. Margaret Knudson, Natasha Bir, Richard Kallet, Keith Atkinson. (2009) Fondaparinux for Prevention of Venous Thromboembolism in High-Risk Trauma Patients: A Pilot Study. Journal of the American College of Surgeons 209:5, 589-594
CrossRef36
Edward E. Winger, Jane L. Reed. (2009) ORIGINAL ARTICLE: A Retrospective Analysis of Fondaparinux Versus Enoxaparin Treatment in Women with Infertility or Pregnancy Loss. American Journal of Reproductive Immunology 62:4, 253-260
CrossRef37
Satoshi Sasaki, Naohisa Miyakoshi, Hiroshi Matsuura, Hidetomo Saitoh, Daisuke Kudoh, Yoichi Shimada. (2009) Prospective randomized controlled trial on the effect of fondaparinux sodium for prevention of venous thromboembolism after hip fracture surgery. Journal of Orthopaedic Science 14:5, 491-496
CrossRef38
Carl-Erik Dempfle, Julia Eichner, Nenad Suvajac, Parviz Ahmad-Nejad, Michael Neumaier, Martin Borggrefe. (2009) The Reduced Anticoagulant Effect of Fondaparinux at Low Antithrombin Levels. Anesthesia & Analgesia 109:3, 712-716
CrossRef39
Greg A. Brown. (2009) Venous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials. The Journal of Arthroplasty 24:6, 77-83
CrossRef40
A. Zancan, C. Locatelli, F. Ramella, P. Tatoni, G. Bacis, S. Vecchio, L. Manzo. (2009) A new model of pharmacovigilance? A pilot study. Biomedicine & Pharmacotherapy 63:6, 451-455
CrossRef41
Alejandro Lazo-Langner, Marc A. Rodger. (2009) Overview of Current Venous Thromboembolism Protocols in Hip Reconstruction. Orthopedic Clinics of North America 40:3, 427-436
CrossRef42
Pieter W. Kamphuisen, Harry R. Büller. 2009. New Heparins: Synthetic Pentasaccharides. , 253-268.
CrossRef43
Alexander GG Turpie, Michael R Lassen, Bruce L Davidson, Kenneth A Bauer, Michael Gent, Louis M Kwong, Fred D Cushner, Paul A Lotke, Scott D Berkowitz, Tiemo J Bandel, Alice Benson, Frank Misselwitz, William D Fisher. (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. The Lancet 373:9676, 1673-1680
CrossRef44
M. R. LASSEN, O. E. DAHL, P. MISMETTI, D. DESTRÉE, A. G. G. TURPIE. (2009) AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery - TREK: a dose-ranging study. Journal of Thrombosis and Haemostasis 7:4, 566-572
CrossRef45
Alexander GG Turpie, Anthonie WA Lensing, Takeshi Fuji, Duane A Boyle. (2009) Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagulation & Fibrinolysis 20:2, 114-121
CrossRef46
Luis Peidro, Francesc Casals, Isabel Real, Daniel Poggio. (2008) Profilaxis de la trombosis en pacientes con antecedentes de enfermedad tromboembólica tributarios de cirugía ortopédica mayor. Medicina Clínica 131, 25-28
CrossRef47
Takeshi Fuji, Takahiro Ochi, Shigeo Niwa, Satoru Fujita. (2008) Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. Journal of Orthopaedic Science 13:5, 442-451
CrossRef48
Kenneth A Bauer. (2008) New anticoagulants. Current Opinion in Hematology 15:5, 509-515
CrossRef49
James W. Heitz, Eugene R. Viscusi. (2008) Neuraxial Anesthesia and Anticoagulants. Techniques in Orthopaedics 23:3, 259-272
CrossRef50
Takeshi Fuji, Satoru Fujita, Takahiro Ochi. (2008) Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. International Orthopaedics 32:4, 443-451
CrossRef51
Sophie Gerkens, Claire Beguin, Ralph Crott, Marie-Christine Closon, Yves Horsmans. (2008) Assessing the quality of pharmacological treatments from administrative databases: the case of low-molecular-weight heparin after major orthopaedic surgery. Journal of Evaluation in Clinical Practice 14:4, 585-594
CrossRef52
Bengt I. Eriksson, Richard J. Friedman, Fred D. Cushner, Michael R. Lassen. (2008) Letter to the Editor. Clinical Orthopaedics and Related Research 466:8, 2009-2011
CrossRef53
Melanie A Abboud, Saul J Needle, Cynthia L Burns-Kurtis, Richard E Valocik, Paul F Koster, Augustin J Amour, Chuen Chan, David Brown, Laiq Chaudry, Ping Zhou, Angela Patikis, Champa Patel, Anthony J Pateman, Rob J Young, Nigel S Watson, John R Toomey. (2008) Antithrombotic Potential of GW813893: A Novel, Orally Active, Active-site Directed Factor Xa Inhibitor. Journal of Cardiovascular Pharmacology 52:1, 66-71
CrossRef54
Richard J. Cook, Bethany J. G. White, Grace Y. Yi, Ker-Ai Lee, Theodore E. Warkentin. (2008) Analysis of a nonsusceptible fraction with current status data. Statistics in Medicine 27:14, 2715-2730
CrossRef55
Lassen, Michael R., Ageno, Walter, Borris, Lars C., Lieberman, Jay R., Rosencher, Nadia, Bandel, Tiemo J., Misselwitz, Frank, Turpie, Alexander G.G., . (2008) Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty. New England Journal of Medicine 358:26, 2776-2786
Full Text56
Emilie V. Cheung, John W. Sperling, Robert H. Cofield. (2008) Infection Associated With Hematoma Formation After Shoulder Arthroplasty. Clinical Orthopaedics and Related Research 466:6, 1363-1367
CrossRef57
Nigel E. Sharrock, Alejandro Gonzalez Della Valle, George Go, Stephen Lyman, Eduardo A. Salvati. (2008) Potent Anticoagulants are Associated with a Higher All-Cause Mortality Rate After Hip and Knee Arthroplasty. Clinical Orthopaedics and Related Research 466:3, 714-721
CrossRef58
Abbas Chamsuddin, Lama Nazzal, Brandon Kang, Irwin Best, Gail Peters, Sepehr Panah, Louis Martin, Curtis Lewis, Chadi Zeinati, John W. Ho, Anthony C. Venbrux. (2008) Catheter-directed Thrombolysis with the Endowave System in the Treatment of Acute Massive Pulmonary Embolism: A Retrospective Multicenter Case Series. Journal of Vascular and Interventional Radiology 19:3, 372-376
CrossRef59
C. Vielpeau, J. Barre, M.-T. Barrellier, A. Borel-Derlon, N. Rosencher, C.M. Samama, M.-M. Samama, P. Zufferey. (2008) Profilaxis de los accidentes tromboemb
licos venosos en cirug
CrossRef60
Clifford W Colwell, Mary E Hardwick. (2008) Thromboprophylaxis in Elderly Patients Undergoing Major Orthopaedic Surgery. Drugs & Aging 25:7, 551-558
CrossRef61
S. Middeldorp. (2008) Heparin: From animal organ extract to designer drug. Thrombosis Research 122:6, 753-762
CrossRef62
Hélène Barreteau, Éric Francois. 2008. Traitement des thromboses veineuses. , 529-561.
CrossRef63
François J. Singelyn, Cees C.P.M. Verheyen, Franco Piovella, Hugo K. Van Aken, Nadia Rosencher. (2007) The Safety and Efficacy of Extended Thromboprophylaxis With Fondaparinux After Major Orthopedic Surgery of the Lower Limb With or Without a Neuraxial or Deep Peripheral Nerve Catheter: The EXPERT Study. Anesthesia & Analgesia 105:6, 1540-1547
CrossRef64
Hui Quan, Daowen Zhang, Ji Zhang, Laure Devlamynck. (2007) Analysis of a binary composite endpoint with missing data in components. Statistics in Medicine 26:26, 4703-4718
CrossRef65
Jean-Pierre Bassand, Isabelle Richard-Lordereau, Yves Cadroy. (2007) Efficacy and safety of fondaparinux in patients with acute coronary syndromes. Expert Review of Cardiovascular Therapy 5:6, 1013-1026
CrossRef66
Eugenia Nikolsky, Gregg W Stone. (2007) Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin. Future Cardiology 3:4, 345-364
CrossRef67
S. M. SCHELLONG, J. BEYER, A. K. KAKKAR, K. HALBRITTER, B. I. ERIKSSON, A. G. G. TURPIE, F. MISSELWITZ, P. KÄLEBO. (2007) Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study. Journal of Thrombosis and Haemostasis 5:7, 1431-1437
CrossRef68
D. J. QUINLAN, J. W. EIKELBOOM, O. E. DAHL, B. I. ERIKSSON, P. S. SIDHU, J. HIRSH. (2007) Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. Journal of Thrombosis and Haemostasis 5:7, 1438-1443
CrossRef69
William E Wade, William J Spruill. (2007) Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism. Expert Review of Pharmacoeconomics & Outcomes Research 7:3, 227-237
CrossRef70
James E. Bradner, John W. Eikelboom. 2007. Emerging Anticoagulants and Heparin-Induced Thrombocytopenia: Indirect and Direct Factor Xa Inhibitors and Oral Thrombin Inhibitors. , 441-462.
CrossRef71
R. Stephen J. Burnett, John C. Clohisy, Rick W. Wright, Douglas J. McDonald, Robert A. Shively, Stephanie A. Givens, Robert L. Barrack. (2007) Failure of the American College of Chest Physicians-1A Protocol for Lovenox in Clinical Outcomes for Thromboembolic Prophylaxis. The Journal of Arthroplasty 22:3, 317-324
CrossRef72
G. AGNELLI, S. HAAS, J. S. GINSBERG, K. A. KRUEGER, A. DMITRIENKO, J. T. BRANDT. (2007) A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. Journal of Thrombosis and Haemostasis 5:4, 746-753
CrossRef73
David Bergqvist. (2007) Mechanical and pharmacological methods to prevent venous thromboembolism. Future Cardiology 3:2, 213-224
CrossRef74
Andrew F. Shorr, Louis M. Kwong, Matthew Sarnes, Laura Happe, Eileen Farrelly, Nikita Mody-Patel. (2007) Venous thromboembolism after orthopedic surgery: Implications of the choice for prophylaxis. Thrombosis Research 121:1, 17-24
CrossRef75
(2007) Invited Synopses. Acute Cardiac Care 9:3, 134-174
CrossRef76
Bruno Tribout, Florence Colin-Mercier. (2007) New versus Established Drugs in Venous Thromboprophylaxis. American Journal of Cardiovascular Drugs 7:1, 1-15
CrossRef77
Matthew L. Ortman, Todd E.H. Hecht. 2007. Prevention of Venous Thromboembolism in the Surgical Patient. , 151-222.
CrossRef78
Alexander GG Turpie. (2006) Fondaparinux in the management of patients with ST-elevation acute myocardial infarction. Vascular Health and Risk Management 2:4, 371-378
CrossRef79
David Bergqvist. (2006) Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery. Vascular Health and Risk Management 2:4, 365-370
CrossRef80
Gregory Piazza, Samuel Z. Goldhaber. (2006) Venous Thromboembolism Guidebook. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 5:4, 211-227
CrossRef81
Clifford W Colwell, Mary E Hardwick. (2006) Rationale for Low-molecular-weight Heparin Prophylaxis after Total Knee Arthroplasty. Clinical Orthopaedics and Related Research 452, 181-185
CrossRef82
AGG Turpie. (2006) Clinical efficacy and safety of fondaparinux: an emphasis on results in the elderly. Aging Health 2:5, 731-743
CrossRef83
CHRISTIAN VON HEYMANN, HELGE SCHOENFELD, MICHAEL SANDER, CLAUDIA SPIES. (2006) New antithrombotics ? pharmacologic profile and implications for anesthesia and surgery. Transfusion Alternatives in Transfusion Medicine 8:3, 164-174
CrossRef84
Dagmar Kubitza, Sylvia Haas. (2006) Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opinion on Investigational Drugs 15:8, 843-855
CrossRef85
Shannon M. Bates, Jeffrey I. Weitz. (2006) The status of new anticoagulants. British Journal of Haematology 134:1, 3-19
CrossRef86
C. Klaeffling, G. Piechottka, G. Daemgen-von Brevern, G. Mosch, H. Mani, B. Luxembourg, E. Lindhoff-Last. (2006) Development and Clinical Evaluation of Two Chromogenic Substrate Methods for Monitoring Fondaparinux Sodium. Therapeutic Drug Monitoring 28:3, 375-381
CrossRef87
Joseph G. Ottinger. (2006) Retrospective Evaluation of Delayed Administration of Fondaparinux in Providing Comparable Safety and Efficacy Outcomes in Patients Undergoing Elective-Arthroplasty Procedures. Hospital Pharmacy 41:4, 348-353
CrossRef88
Rakesh P. Mehta, Matthew S. Johnson. (2006) Update on Anticoagulant Medications for the Interventional Radiologist. Journal of Vascular and Interventional Radiology 17:4, 597-612
CrossRef89
Sean D. Sullivan, Louis Kwong, Edith Nutescu. (2006) Cost-Effectiveness of Fondaparinux Compared with Enoxaparin as Prophylaxis against Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery. Value in Health 9:2, 68-76
CrossRef90
Cedric Hermans, Donald Claeys. (2006) Review of the rebound phenomenon in new anticoagulant treatments. Current Medical Research and Opinion 22:3, 471-481
CrossRef91
Kenneth A. Bauer. (2006) New Anticoagulants: Anti IIa vs Anti Xa—Is One Better?. Journal of Thrombosis and Thrombolysis 21:1, 67-72
CrossRef92
Bengt I Eriksson, Daniel J Quinlan. (2006) Oral Anticoagulants in Development. Drugs 66:11, 1411-1429
CrossRef93
2006. Fondaparinux. , 1437-1439.
CrossRef94
David Garcia, Walter Ageno, Edward Libby. (2005) Update on the diagnosis and management of pulmonary embolism. British Journal of Haematology 131:3, 301-312
CrossRef95
Hervé Decousus, Karine Rivron-Guillot, Gaelle Girard, Nathalie Moulin. (2005) Clinical efficacy and safety of fondaparinux in the prevention and treatment of venous and arterial thrombosis. Future Cardiology 1:6, 743-758
CrossRef96
A. G. G. TURPIE, W. D. FISHER, K. A. BAUER, L. M. KWONG, M. W. IRWIN, P. KALEBO, F. MISSELWITZ, M. GENT, . (2005) BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. Journal of Thrombosis and Haemostasis 3:11, 2479-2486
CrossRef97
G. Agnelli, D. Bergqvist, A. T. Cohen, A. S. Gallus, M. Gent, . (2005) Randomized clinical trial of postoperative fondaparinuxversus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. British Journal of Surgery 92:10, 1212-1220
CrossRef98
Andreas Pingsmann, Ruth Blatt, Steffen Breusch, Christian J??rgens, Roland Thietje, Andreas Kr??del, Wolfgang Zinser, Ivo Michiels, Fritz U. Niethard, Christopher Niedhart, Katrin Renzing-K??hler, Hans-Joachim Pfefferle. (2005) Efficacy and Safety of a Novel Moldable, Resorbable, and Degradable Sealant of Bone Surfaces for Hemostasis After Bone Graft Harvesting From the Iliac Crest. Spine 30:17, 1911-1917
CrossRef99
Thomas M. Hyers. (2005) Heparin and Other Rapidly Acting Anticoagulants. Seminars in Vascular Surgery 18:3, 130-133
CrossRef100
J. I. WEITZ, S. M. BATES. (2005) New anticoagulants. Journal of Thrombosis and Haemostasis 3:8, 1843-1853
CrossRef101
Jeanine M Walenga, Walter P Jeske, Jawed Fareed. (2005) Short- and long-acting synthetic pentasaccharides as antithrombotic agents. Expert Opinion on Investigational Drugs 14:7, 847-858
CrossRef102
Alexander GG Turpie. (2005) The safety of fondaparinux for the prevention and treatment of venous thromboembolism. Expert Opinion on Drug Safety 4:4, 707-721
CrossRef103
Joanne E. Joseph, Joyce Low, Brett Courtenay, Michael J. Neil, Michael McGrath, David Ma. (2005) A single-centre prospective study of clinical and haemostatic risk factors for venous thromboembolism following lower limb arthroplasty. British Journal of Haematology 129:1, 87-92
CrossRef104
R. M. Bauersachs. (2005) Fondaparinux: an update on new study results. European Journal of Clinical Investigation 35:s1, 27-32
CrossRef105
L. Drouet, C. Bal dit Sollier. (2005) Rationale for the use of antifactor Xa in the treatment and prevention of venous and arterial thromboembolic events. European Journal of Clinical Investigation 35:s1, 21-26
CrossRef106
P. Bramlage, D. Pittrow, W. Kirch. (2005) Current concepts for the prevention of venous thromboembolism. European Journal of Clinical Investigation 35:s1, 4-11
CrossRef107
V. RAJAGOPAL, D. L. BHATT. (2005) Factor Xa inhibitors in acute coronary syndromes: moving from mythology to reality. Journal of Thrombosis and Haemostasis 3:3, 436-438
CrossRef108
S. Alban. (2005) From heparins to factor Xa inhibitors and beyond. European Journal of Clinical Investigation 35:s1, 12-20
CrossRef109
R. D. FRANK, G. SCHABBAUER, T. HOLSCHER, Y. SATO, M. TENCATI, R. PAWLINSKI, N. MACKMAN. (2005) The synthetic pentasaccharide fondaparinux reduces coagulation, inflammation and neutrophil accumulation in kidney ischemia-reperfusion injury. Journal of Thrombosis and Haemostasis 3:3, 531-540
CrossRef110
A. E. Handschin, O. A. Trentz, S. P. Hoerstrup, H. J. Kock, G. A. Wanner, O. Trentz. (2005) Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra
CrossRef111
Rachel P. Rosovsky, David J. Kuter. (2005) Catheter-Related Thrombosis in Cancer Patients: Pathophysiology, Diagnosis, and Management. Hematology/Oncology Clinics of North America 19:1, 183-202
CrossRef112
Thomas D. Szucs, Walter E. Kaiser, Felix Mahler, Felix Gutzwiller. (2005) Thromboembolic Prophylaxis with Fondaparinux in Major Orthopaedic Surgery: Outcomes and Costs. Heart Drug 5:3, 121-130
CrossRef113
Anne Grand???Maison, Andre F Charest, William H Geerts. (2005) Anticoagulant Use in Patients with Chronic Renal Impairment. American Journal of Cardiovascular Drugs 5:5, 291-305
CrossRef114
Afsane Bjorvatn, Frode Kristiansen. (2005) Fondaparinux Sodium Compared with Enoxaparin Sodium. American Journal of Cardiovascular Drugs 5:2, 121-130
CrossRef115
Elizabeth Blanchard, Jack Ansell. (2005) Extended Anticoagulation Therapy for the Primary and Secondary Prevention of Venous Thromboembolism. Drugs 65:3, 303-311
CrossRef116
John H Alexander, Kanwar P Singh. (2005) Inhibition of Factor Xa. American Journal of Cardiovascular Drugs 5:5, 279-290
CrossRef117
Carsten N. Gutt, Traian Oniu, Frédéric Wolkener, Ari Mehrabi, Shilu Mistry, Markus W. Büchler. (2005) Prophylaxis and treatment of deep vein thrombosis in general surgery. The American Journal of Surgery 189:1, 14-22
CrossRef118
Lynn M Broadman. (2005) Anticoagulation and Regional Anesthesia. ASA Refresher Courses in Anesthesiology 33:1, 31-47
CrossRef119
Clifford W. Colwell, Mary E. Hardwick. (2004) Low-Molecular-Weight Heparin Prophylaxis in Major Orthopaedic Surgery of the Lower Extremity. Techniques in Orthopaedics 19:4, 275-277
CrossRef120
James Edwin Muntz. (2004) Fondaparinux for Prophylaxis. Techniques in Orthopaedics 19:4, 278-282
CrossRef121
C HANTLER, G DESPOTIS, R SINHA, J CHELLY. (2004) Guidelines and alternatives for neuraxial anesthesia and venous thromboembolism prophylaxis in major orthopedic surgery. The Journal of Arthroplasty 19:8, 1004-1016
CrossRef122
James Muntz, David A Scott, Adam Lloyd, Matthias Egger. (2004) Major bleeding rates after prophylaxis against venous thromboembolism: Systematic review, meta-analysis, and cost implications. International Journal of Technology Assessment in Health Care 20:04,
CrossRef123
A. Y. Y. Lee, M. Gent, J. A. Julian, K. A. Bauer, B. I. Eriksson, M. R. Lassen, A. G. G. Turpie. (2004) Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review. Journal of Thrombosis and Haemostasis 2:10, 1752-1759
CrossRef124
Liguo Chi, Yun-Wen Peng, Glenn Gibson, Gary Hicks, Thomas E Mertz, Stephen Rapundalo, Nancy Janiczek, Jeremy J Edmunds, Robert Leadley. (2004) In Vitro and In Vivo Antithrombotic Activity of PD-198961, a Novel Synthetic Factor Xa Inhibitor. Journal of Cardiovascular Pharmacology 44:4, 493-500
CrossRef125
David Bergqvist. (2004) Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management. European Journal of Haematology 73:4, 227-242
CrossRef126
Patrick Haentjens, Katrien De Groote, Lieven Annemans. (2004) Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.. Archives of Orthopaedic and Trauma Surgery 124:8, 507-517
CrossRef127
William J Spruill, William E Wade, Ryan B Leslie. (2004) Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in elective hip replacement surgery. Blood Coagulation & Fibrinolysis 15:7, 539-543
CrossRef128
K BEREND. (2004) Ileus following total hip or knee arthroplasty is associated with increased risk of deep venous thrombosis and pulmonary embolism*1. The Journal of Arthroplasty 19:7, 82-86
CrossRef129
M Nijkeuter, M V Huisman. (2004) Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review. Current Opinion in Pulmonary Medicine 10:5, 338-344
CrossRef130
G. Di Minno, A. Tufano. (2004) Challenges in the prevention of venous thromboembolism in the elderly. Journal of Thrombosis and Haemostasis 2:8, 1292-1298
CrossRef131
David Hawkins. (2004) Pharmacoeconomics of Thrombosis Management. Pharmacotherapy 24:7 Part 2, 95S-99S
CrossRef132
William E. Dager, Judith Andersen, Edith Nutescu. (2004) Special Considerations with Fondaparinux Therapy: Heparin-Induced Thrombocytopenia and Wound Healing. Pharmacotherapy 24:7 Part 2, 88S-94S
CrossRef133
Bob L. Lobo. (2004) Emerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data. Pharmacotherapy 24:7 Part 2, 66S-72S
CrossRef134
David E. Kandzari. (2004) Current concepts in the antithrombotic management of non-ST-elevation acute coronary syndromes. Current Cardiology Reports 6:4, 279-286
CrossRef135
Hau C Kwaan, Meyer M Samama. (2004) Anticoagulant drugs: an update. Expert Review of Cardiovascular Therapy 2:4, 511-522
CrossRef136
Maarten L. Simoons, Inge W.G. Bobbink, Jean Boland, Martin Gardien, Peter Klootwijk, Anthonie W.A. Lensing, Witold Ruzyllo, Victor A.W.M. Umans, Alec Vahanian, Frans Van De Werf, Uwe Zeymer. (2004) A dose-finding study of fondaparinux in patients with non–ST-segment elevation acute coronary syndromes. Journal of the American College of Cardiology 43:12, 2183-2190
CrossRef137
Alexander GG Turpie. (2004) Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy. Expert Opinion on Pharmacotherapy 5:6, 1373-1384
CrossRef138
Juan F. Viles-Gonzalez, Sunil X. Anand, M. Urooj Zafar, Valentin Fuster, Juan J. Badimon. (2004) Tissue Factor Coagulation Pathway: A New Therapeutic Target in Atherothrombosis. Journal of Cardiovascular Pharmacology 43:5, 669-676
CrossRef139
A.G.G. Turpie. (2004) The design of venous thromboembolism prophylaxis trials: Fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery. International Journal of Clinical Practice 58:5, 483-493
CrossRef140
Thomas Hofmann. (2004) Clinical application of enoxaparin. Expert Review of Cardiovascular Therapy 2:3, 321-337
CrossRef141
Dempfle, Carl-Erik H., . (2004) Minor Transplacental Passage of Fondaparinux in Vivo. New England Journal of Medicine 350:18, 1914-1915
Full Text142
Samuel Z Goldhaber. (2004) Pulmonary embolism. The Lancet 363:9417, 1295-1305
CrossRef143
Kenneth A Bauer. (2004) Fondaparinux: a new synthetic and selective inhibitor of Factor Xa. Best Practice & Research Clinical Haematology 17:1, 89-104
CrossRef144
D.F. O'Shaughnessy. (2004) Current perspectives on the treatment of venous thromboembolism: need for effective, safe and convenient new antithrombotic drugs. International Journal of Clinical Practice 58:3, 277-284
CrossRef145
Nick R. Bijsterveld, Roel Vink, Benien E. van Aken, Hein Fennema, Ron J. G. Peters, Joost C. M. Meijers, Harry R. Buller, Marcel Levi. (2004) Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. British Journal of Haematology 124:5, 653-658
CrossRef146
Ajay K Kakkar. (2004) Low- and ultra-low-molecular-weight heparins. Best Practice & Research Clinical Haematology 17:1, 77-87
CrossRef147
Jonathan L Halperin. (2004) Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor. Expert Review of Cardiovascular Therapy 2:2, 163-174
CrossRef148
Victor J Marder, Michael H Rosove, Dena M Minning. (2004) Foundation and sites of action of antithrombotic agents. Best Practice & Research Clinical Haematology 17:1, 3-22
CrossRef149
Grigoris T Gerotziafas, Fran??ois Depasse, Tahar Chakroun, Patrick Van Dreden, Meyer M Samama, Ismail Elalamy. (2004) Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma. Blood Coagulation & Fibrinolysis 15:2, 149-156
CrossRef150
(2004) Ximelagatran versus Warfarin after Total Knee Replacement. New England Journal of Medicine 350:6, 616-617
Full Text151
Leno Thomas, Young Kwok, Martin J. Edelman. (2004) Management of paraneoplastic syndromes in lung cancer. Current Treatment Options in Oncology 5:1, 51-62
CrossRef152
(2004) A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis 2:1, 47-53
CrossRef153
William J. Spruill, William E. Wade, Ryan B. Leslie. (2004) A Cost Analysis of Fondaparinux Versus Enoxaparin in Total Knee Arthroplasty. American Journal of Therapeutics 11:1, 3-8
CrossRef154
Sean D Sullivan, Bruce L Davidson, Susan R Kahn, James E Muntz, Gerry Oster, Gary Raskob. (2004) A Cost-Effectiveness Analysis of Fondaparinux Sodium Compared with Enoxaparin Sodium as Prophylaxis Against Venous Thromboembolism. PharmacoEconomics 22:9, 605-620
CrossRef155
Craig M Kessler. (2004) Current and future challenges of antithrombotic agents and anticoagulants: strategies for reversal of hemorrhagic complications. Seminars in Hematology 41, 44-50
CrossRef156
George Dranitsaris, Susan R Kahn, Carmine Stumpo, Thomas W Paton, Josee Martineau, Reginald Smith, Jeffrey S Ginsberg. (2004) Pharmacoeconomic Analysis of Fondaparinux Versus Enoxaparin for the Prevention of Thromboembolic Events in Orthopedic Surgery Patients. American Journal of Cardiovascular Drugs 4:5, 325-333
CrossRef157
Karl-Georg Fischer. (2004) The Role of Recombinant Hirudins in the Management of Thrombotic Disorders. BioDrugs 18:4, 235-268
CrossRef158
Juan F Viles-Gonzalez, Juan Gaztanaga, Urooj M Zafar, Valentin Fuster, Juan J Badimon. (2004) Clinical and Experimental Experience with Factor Xa Inhibitors. American Journal of Cardiovascular Drugs 4:6, 379-384
CrossRef159
B. I. Eriksson, G. Agnelli, A. T. Cohen, O. E. Dahl, M. R. Lassen, P. Mouret, N. Rosencher, P. Kalebo, S. Panfilov, C. Eskilson, M. Andersson, . (2003) The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. Journal of Thrombosis and Haemostasis 1:12, 2490-2496
CrossRef160
P. Mismetti. (2003) Prevention of venous thromboembolism after major orthopedic surgery: 'new' clinical trials for new antithrombotic agents. Journal of Thrombosis and Haemostasis 1:12, 2474-2476
CrossRef161
Alfred J. Tria, Thomas M. Coon. (2003) Minimal Incision Total Knee Arthroplasty: Early Experience. Clinical Orthopaedics and Related Research 416, 185-190
CrossRef162
A Bura-Riviere, J.-N Fiessinger. (2003) Les nouveaux anticoagulants dans la maladie thromboembolique veineuse. La Revue de Médecine Interne 24:11, 738-744
CrossRef163
T. Lisman, N. R. Bijsterveld, J. Adelmeijer, J. C. M. Meijers, M. Levi, H. K. Nieuwenhuis, P. G. De Groot. (2003) Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. Journal of Thrombosis and Haemostasis 1:11, 2368-2373
CrossRef164
Francis, Charles W., Berkowitz, Scott D., Comp, Philip C., Lieberman, Jay R., Ginsberg, Jeffrey S., Paiement, Guy, Peters, Gary R., Roth, Anne W., McElhattan, Jennifer, Colwell, Clifford W. Jr., . (2003) Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement. New England Journal of Medicine 349:18, 1703-1712
Full Text165
A. Gordois, J. Posnett, L. Borris, P. Bossuyt, B. Jonsson, E. Levy, G. De Pouvourville. (2003) The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. Journal of Thrombosis and Haemostasis 1:10, 2167-2174
CrossRef166
M. M. W. Koopman, H. R. Buller. (2003) Short- and long-acting synthetic pentasaccharides. Journal of Internal Medicine 254:4, 335-342
CrossRef167
E. Rocha, A. Planes. (2003) Rebuttal to: LMWH vs. LMWH: superior, equivalent or non-inferior?. Journal of Thrombosis and Haemostasis 1:10, 2256-2258
CrossRef168
Alexander G.G. Turpie, Bengt I. Eriksson, Michael R. Lassen, Kenneth A. Bauer. (2003) Fondaparinux, the first selective factor Xa inhibitor. Current Opinion in Hematology 10:5, 327-332
CrossRef169
Gordon DO Lowe, Peter AG Sandercock, Frits R Rosendaal. (2003) Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance?. The Lancet 362:9383, 504-505
CrossRef170
Nina N. Wong. (2003) Fondaparinux. Heart Disease 5:4, 295-302
CrossRef171
Philip C. Comp. (2003) Selective Factor Xa Inhibition Improves Efficacy of Venous Thromboembolism Prophylaxis in Orthopedic Surgery. Pharmacotherapy 23:6, 772-787
CrossRef172
Kiat Tsong Tan, Andrew Makin, Gregory YH Lip. (2003) Factor X inhibitors. Expert Opinion on Investigational Drugs 12:5, 799-804
CrossRef173
Timothy A Morris. (2003) Heparin and low molecular weight heparin: background and pharmacology. Clinics in Chest Medicine 24:1, 39-47
CrossRef174
H. Bounameaux, A. Perrier. (2003) LMWH contra LMWH: superior, equivalent or non-inferior?. Journal of Thrombosis and Haemostasis 1:3, 414-415
CrossRef175
Sheila A Doggrell. (2003) Reviparin as prophylaxis for thromboembolism after leg injury and hip replacement. Expert Opinion on Pharmacotherapy 4:2, 285-288
CrossRef176
Peter Kaboli, Mark C Henderson, Richard H White. (2003) DVT prophylaxis and anticoagulation in the surgical patient. Medical Clinics of North America 87:1, 77-110
CrossRef177
Hugh C. Gilbert. (2003) Complications and Controversies in Regional Anesthesia. ASA Refresher Courses in Anesthesiology 31:1, 45-64
CrossRef178
Hugh C. Gilbert. (2003) CHAPTER 6 Complications and Controversies in Regional Anesthesia. ASA Refresher Courses in Anesthesiology 31:1, 43-65
CrossRef179
Jeffrey I Weitz, Mark A Crowther. (2003) New Anticoagulants. American Journal of Cardiovascular Drugs 3:3, 201-209
CrossRef180
Meyer-Michel Samama, Grigoris T. Gerotziafas. (2003) Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thrombosis Research 109:1, 1-11
CrossRef181
Susan I. O'Shea, Thomas L. Ortel, Eugene C. Kovalik. (2003) HEPARIN-INDUCED THROMBOCYTOPENIA IN DIALYSIS: Alternative Methods of Anticoagulation for Dialysis-dependent Patients with Heparin-induced Thrombocytopenia. Seminars in Dialysis 16:1, 61-67
CrossRef182
Shannon M Bates. (2002) Treatment and prophylaxis of venous thromboembolism during pregnancy. Thrombosis Research 108:2-3, 97-106
CrossRef183
Jan P Vandenbroucke. (2002) Do editors live up to the Sept 10, 2001, expectations?. The Lancet 360:9345, 1605-1606
CrossRef184
Stefan Viktor Vormfelde. (2002) Enoxaparin or fondaparinux for thrombosis prevention after orthopaedic surgery. The Lancet 360:9346, 1701
CrossRef185
Judy W.M. Cheng. (2002) Fondaparinux: A new antithrombotic agent. Clinical Therapeutics 24:11, 1757-1769
CrossRef186
MR Lassen, AGG Turpie. (2002) Fondaparinux versus enoxaparin for prevention of venous thromboembolism. The Lancet 360:9345, 1605
CrossRef187
MR Lassen, AGG Turpie, KA Bauer, BI Eriksson. (2002) Do editors live up to the Sept 10, 2001, expectations?. The Lancet 360:9345, 1606
CrossRef188
Graham F. Pineo, Russell D. Hull. (2002) Pulmonary vascular disease. Current Opinion in Pulmonary Medicine 8:5, 357-359
CrossRef189
Kenneth A. Bauer, Bengt I. Eriksson, Michael R. Lassen, Alexander G.G. Turpie. (2002) Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism. Current Opinion in Pulmonary Medicine 8:5, 398-404
CrossRef190
Lori-Ann Linkins, Jim A Julian, Janice Rischke, Jack Hirsh, Jeffrey I Weitz. (2002) In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thrombosis Research 107:5, 241-244
CrossRef191
Alexander S. Gallus, Douglas W. Coghlan. (2002) Heparin pentasaccharide. Current Opinion in Hematology 9:5, 422-429
CrossRef192
Frederick B. Rogers, Mark D. Cipolle, George Velmahos, Grace Rozycki, Fred A. Luchette. (2002) Practice Management Guidelines for the Prevention of Venous Thromboembolism in Trauma Patients: The EAST Practice Management Guidelines Work Group. The Journal of Trauma: Injury, Infection, and Critical Care 53:1, 142-164
CrossRef193
Alexander G.G. Turpie. (2002) Pentasaccharides. Seminars in Hematology 39:3, 158-171
CrossRef194
Henri Bounameaux, Thomas Perneger. (2002) Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. The Lancet 359:9319, 1710-1711
CrossRef195
Michael Rud Lassen, Kenneth A Bauer, Bengt I Eriksson, Alexander GG Turpie. (2002) Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. The Lancet 359:9319, 1715-1720
CrossRef196
Hannu I Manninen. (2002) Time for more complete scoring of deep leg vein thrombosis. Acta Radiologica 43:3, 239-240
CrossRef197
Alexander GG Turpie, Kenneth A Bauer, Bengt I Eriksson, Michael R Lassen. (2002) Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. The Lancet 359:9319, 1721-1726
CrossRef198
Meyer Michel Samama. (2002) Synthetic direct and indirect factor Xa inhibitors. Thrombosis Research 106:3, V267-V273
CrossRef199
. (2002) Fondaparinux – een nieuw parenteraal antistollingsmiddel. Medisch-Farmaceutische Mededelingen 40:4, 113-114
CrossRef200
Mats Eriksson, Kjeld Christensen, Tomas L Lindahl, Anders Larsson. (2002) Pharmaceutical thrombosis prevention in cardiovascular disease. Expert Opinion on Investigational Drugs 11:4, 553-563
CrossRef201
Sheila A Doggrell. (2002) Fondaparinux versus enoxaparin for the prevention of venous thromboembolism. Expert Opinion on Pharmacotherapy 3:4, 455-457
CrossRef202
(2002) Prevention of Venous Thromboembolism with Fondaparinux. New England Journal of Medicine 346:12, 940-942
Full Text203
Kenneth A. Bauer, David W. Hawkins, Paul C. Peters, Maurice Petitou, Jean-Marc Herbert, Constant A. A. Boeckel, Dirk G. Meuleman. (2002) Fondaparinux, a Synthetic Pentasaccharide: The First in a New Class of Antithrombotic Agents - The Selective Factor Xa Inhibitors. Cardiovascular Drug Reviews 20:1, 37-52
CrossRef204
Jeanine M Walenga, Walter P Jeske, F Xavier Frapaise, Rodger L Bick, Jawed Fareed, M Michel Samama. (2002) Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opinion on Investigational Drugs 11:3, 397-407
CrossRef205
Fran??ois Donat, Jean Pierre Duret, Alix Santoni, Roger Cariou, Jos?? Necciari, Harry Magnani, Rik de Greef. (2002) The Pharmacokinetics of Fondaparinux Sodium in Healthy Volunteers. Clinical Pharmacokinetics 41:Supplement 2, 1-9
CrossRef206
Fabrice Lagrange, Jean-Luc Brun, Marie Christine Vergnes, Francis Paolucci, Teresa Nadal, Jean-Joel Leng, Marie Claude Saux, Bernard Bannwarth. (2002) Fondaparinux Sodium Does Not Cross the Placental Barrier*. Clinical Pharmacokinetics 41:Supplement 2, 47-49
CrossRef207
Timothy Mant, Philippe Fourni??, C??line Ollier, Fran??ois Donat, Jos?? Necciari. (2002) Absence of Interaction of Fondaparinux Sodium with Digoxin in Healthy Volunteers. Clinical Pharmacokinetics 41:Supplement 2, 39-45
CrossRef208
Carolyne Lieu, Juan Shi, Fran??ois Donat, Robert Van Horn, William Brian, John Newton, Leon Delbressine, Ria Vos. (2002) Fondaparinux Sodium Is Not Metabolised in Mammalian Liver Fractions and Does Not Inhibit Cytochrome P450-Mediated Metabolism of Concomitant Drugs. Clinical Pharmacokinetics 41:Supplement 2, 19-26
CrossRef209
Francis Paolucci, Marie-Christine Clavi??s, Fran??ois Donat, Jos?? Necciari. (2002) Fondaparinux Sodium Mechanism of Action. Clinical Pharmacokinetics 41:Supplement 2, 11-18
CrossRef210
Diuguid, David L., . (2001) Choosing a Parenteral Anticoagulant Agent. New England Journal of Medicine 345:18, 1340-1342
Full Text211
&NA;. (2001) Hip and knee surgery: which parenteral anticoagulant to use?. Inpharma Weekly &NA;:1313, 8
CrossRef
